Halozyme Therapeutics Inc (HALO) valuation · P/E 36, rev $1.40B
Halozyme Therapeutics Inc (HALO) P/E 36, rev $1.40B.
| Metric | Value |
|---|---|
| P/E | 36 |
| Market cap | $7.10B |
| Revenue | $1.40B |
| P/S | 5.1 |
HALO valuation FAQ
What is HALO's P/E ratio?
Halozyme Therapeutics Inc (HALO) trailing P/E is 36 on the latest cached fundamentals snapshot.
What is HALO's market cap?
Halozyme Therapeutics Inc (HALO) market cap is $7.10B on the latest cached fundamentals snapshot.
What is HALO's latest revenue?
Latest cached Halozyme Therapeutics Inc (HALO) revenue was $1.40B. Statements: https://lician.com/financials/halo
What is HALO's price-to-sales ratio?
Halozyme Therapeutics Inc (HALO) price-to-sales (P/S) is 5.1, cached market cap $7.10B divided by revenue $1.40B.
How many HALO valuation scalars are listed on this page?
This page lists 4 cached valuation scalars for Halozyme Therapeutics Inc (HALO): P/E, Market cap, Revenue, and P/S.
Where is HALO valuation listed?
Cached valuation multiples for Halozyme Therapeutics Inc (HALO) are listed at https://lician.com/valuation/halo.
Not investment advice. Cached rows, not a live tape.